Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | US$121.93B | -230.9x | 2.05 | US$474.62 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.8% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$61.47B | 14.2x | 1.51 | US$572.91 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$43.12B | 58x | US$58.86 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$34.81B | 41.3x | 0.13 | US$555.11 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$28.42B | -44.4x | -1.62 | US$238.51 | -9.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | US$27.42B | 20.8x | 8.3 | US$154.73 | -7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.1% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$21.18B | -29.1x | 0.18 | US$87.92 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$13.95B | -59.7x | -0.98 | US$17.27 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$13.16B | 11.1x | 0.47 | US$292.46 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.5% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$13.09B | 31.2x | 35.47 | US$3.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$13.09B | 31.2x | 35.47 | US$5.76 | -8.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.54B | -12.4x | 3.58 | US$69.18 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.9% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.43B | 16.2x | 0.63 | US$153.69 | -6.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.8% Upside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.73B | 10.3x | 0.13 | US$18.39 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.4% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.75B | -2.7x | -0.14 | US$25.11 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.68B | 19.4x | 0.12 | US$34.57 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.3% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.51B | 28.1x | 1 | US$95.65 | -7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.98B | -22.1x | -0.96 | US$142.67 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.77B | 22.1x | 0.56 | US$287.20 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.8% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | US$8.28B | 98.1x | -1.35 | US$38.26 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.18B | 52.8x | -1.99 | US$51.72 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.99B | -7.8x | 0.23 | US$42.58 | -7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.8% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.98B | -7.7x | 0.02 | US$42.53 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.95B | -14.4x | 1.63 | US$314.39 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.8% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | US$6.76B | 690.6x | -7.9 | US$136.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.86B | -32.2x | -0.54 | US$32.01 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.84B | -8.8x | -1.6 | US$31.29 | -4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
TG | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.43B | 232.9x | 3.64 | US$37.29 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.28B | 22.2x | 0.21 | US$54.43 | -7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.23B | -75.6x | -0.97 | US$81.68 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.2% Upside | Upgrade to Pro+ | |
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.94B | -30.5x | 0.15 | US$53.90 | -7.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.93B | 54.3x | 0.09 | US$171.30 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.7% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.89B | 13.4x | 4.18 | US$30.04 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.81B | 190.5x | 0.23 | US$13.61 | -15.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.6% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.74B | -16.7x | 0.25 | US$65.74 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.46B | -7.1x | -2.52 | US$37.35 | -7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.31B | -8.9x | 0.58 | US$27.09 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.13B | -57.5x | 0.07 | US$17.30 | -9.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | US$4.10B | -8.7x | -2.36 | US$31.60 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.43B | -32.3x | 0.96 | US$58.59 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.11B | -15.6x | 0.22 | US$67.47 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.4% Upside | Upgrade to Pro+ | |
Ultragenyx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.01B | -5.2x | -0.26 | US$32.43 | -7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Rhythm Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.98B | -10.8x | 0.37 | US$46.86 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.94B | -9.9x | 0.45 | US$36.73 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SpringWorks | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.94B | -11.1x | -0.42 | US$39.06 | -9.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.80B | -11.2x | -0.19 | US$8.50 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.79B | -7.5x | 0.07 | US$32.65 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.73B | 10x | 0.03 | US$44.44 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.4% Upside | Upgrade to Pro+ | |
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.65B | -11x | 1.23 | US$38.14 | -8.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.57B | 11.3x | 0.03 | US$15.37 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |